Eirini Keskilidou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Eirini Keskilidou has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Efthymia Protonotariou
Department of Microbiology, AHEPA University Hospital, Thessaloniki, Greece
3 shared publicationsLemonia Skoura
Department of Microbiology, AHEPA University Hospital, Thessaloniki, Greece
3 shared publications- Paraskevi Mantzana
Department of Microbiology, AHEPA University Hospital, School of Medicine, Aristotle University of Thessaloniki, Greece
3 shared publications - Adonis A. Protopapas
First Propaedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, Greece
2 shared publications - Areti Kourti
Laboratory of Biological Chemistry, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, GR-54124 Thessaloniki, Greece
2 shared publications Christiana Gogou
First Medical Propedeutic Department of Internal Medicine, AHEPA University Hospital, Thessaloniki, Greece
2 shared publications
Latest Publications
- Open Access
- 1 June 2026
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 16 (6) , 300
GDF-15: Can It Be Used as a Biomarker in Acute Cerebrovascular Incidents?
Background/Objectives: Growth differentiation factor-15 (GDF-15) is a protein that belongs to the transforming growth factor beta superfamily and has been found elevated in cases of organ injury such as liver, kidney, heart, and lung, as well as cardiovascular diseases and cancer. Soluble urokinase plasminogen activator receptor (suPAR) is a protein which is expressed mainly on immune cells and endothelial and smooth muscle cells, and is a marker of severity and intensity of inflammation in acute and chronic diseases. The aim of the present study was to compare GDF-15 serum levels between patients with acute cerebrovascular incidents and healthy controls and to investigate the possible correlation of GDF-15 serum levels and inflammatory markers, such as serum C-reactive protein (CRP) and plasma suPAR, in the above-mentioned groups. Methods: This is a retrospective study. Thirty-one patients were included in the study, with a mean age ± SD of 67 ± 13 years, compared to 18 age-matched healthy controls. Results: In the patient group a statistically significant positive correlation of serum levels of GDF15 values with suPAR and CRP emerged (rs = 0.516, p = 0.003) and (rs = 0.409, p = 0.022), respectively, and no significant correlation was found in the group of controls (rs = 0.271, p = 0.277) and (rs = 0.423, p = 0.080), respectively. Conclusions: These findings support the role of inflammation as a key underlying mechanism in acute cerebrovascular injury and suggest that GDF-15 may serve as a valuable adjunct biomarker for assessing disease severity and inflammatory burden.
- 1 June 2026
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 16 (6) , 300
Open AccessGDF-15: Can It Be Used as a Biomarker in Acute Cerebrovascular Incidents?
Background/Objectives: Growth differentiation factor-15 (GDF-15) is a protein that belongs to the transforming growth factor beta superfamily and has been found elevated in cases of organ injury such as liver, kidney, heart, and lung, as well as cardiovascular diseases and cancer. Soluble urokinase plasminogen activator receptor (suPAR) is a protein which is expressed mainly on immune cells and endothelial and smooth muscle cells, and is a marker of severity and intensity of inflammation in acute and chronic diseases. The aim of the present study was to compare GDF-15 serum levels between patients with acute cerebrovascular incidents and healthy controls and to investigate the possible correlation of GDF-15 serum levels and inflammatory markers, such as serum C-reactive protein (CRP) and plasma suPAR, in the above-mentioned groups. Methods: This is a retrospective study. Thirty-one patients were included in the study, with a mean age ± SD of 67 ± 13 years, compared to 18 age-matched healthy controls. Results: In the patient group a statistically significant positive correlation of serum levels of GDF15 values with suPAR and CRP emerged (rs = 0.516, p = 0.003) and (rs = 0.409, p = 0.022), respectively, and no significant correlation was found in the group of controls (rs = 0.271, p = 0.277) and (rs = 0.423, p = 0.080), respectively. Conclusions: These findings support the role of inflammation as a key underlying mechanism in acute cerebrovascular injury and suggest that GDF-15 may serve as a valuable adjunct biomarker for assessing disease severity and inflammatory burden.
- Open Access
- 23 February 2026
- Published by Journal of Biological Methods in Journal of Biological Methods
- Vol. 13 (1) , e99010099
Comparative measurement of plasma soluble urokinase plasminogen activator receptor using a point-of-care device and a clinical analyzer in stroke patients
Background: Soluble urokinase plasminogen activator receptor (suPAR) reflects immune activation and chronic inflammatory responses and has been proposed as a prognostic biomarker in several acute conditions. Objectives: This study aims to evaluate the clinical performance of two analytical methods for plasma suPAR determination in patients with stroke: a point-of-care (POC) lateral-flow assay and an automated particle-enriched turbidimetric immunoassay performed on a biochemistry analyzer. Methods: Plasma samples from 27 patients with stroke and 14 age-matched healthy controls were analyzed with both methods. suPAR concentrations were significantly higher in stroke patients compared with controls for both assays. Results: A statistically significant difference between POC and analyzer measurements was observed only within the stroke group (p=0.024), and a strong positive correlation between the two methods was identified (r = 0.745, p<0.001). Receiver operating characteristic analysis demonstrated higher sensitivity for the POC method (96%) compared with the analyzer (82%), while the specificity was identical (57%). Conclusion: These findings suggest that suPAR measurement using a rapid POC platform provides reliable results and may support early risk stratification in patients with stroke in emergency department settings.
- 23 February 2026
- Published by Journal of Biological Methods in Journal of Biological Methods
- Vol. 13 (1) , e99010099
Open AccessComparative measurement of plasma soluble urokinase plasminogen activator receptor using a point-of-care device and a clinical analyzer in stroke patients
Background: Soluble urokinase plasminogen activator receptor (suPAR) reflects immune activation and chronic inflammatory responses and has been proposed as a prognostic biomarker in several acute conditions. Objectives: This study aims to evaluate the clinical performance of two analytical methods for plasma suPAR determination in patients with stroke: a point-of-care (POC) lateral-flow assay and an automated particle-enriched turbidimetric immunoassay performed on a biochemistry analyzer. Methods: Plasma samples from 27 patients with stroke and 14 age-matched healthy controls were analyzed with both methods. suPAR concentrations were significantly higher in stroke patients compared with controls for both assays. Results: A statistically significant difference between POC and analyzer measurements was observed only within the stroke group (p=0.024), and a strong positive correlation between the two methods was identified (r = 0.745, p<0.001). Receiver operating characteristic analysis demonstrated higher sensitivity for the POC method (96%) compared with the analyzer (82%), while the specificity was identical (57%). Conclusion: These findings suggest that suPAR measurement using a rapid POC platform provides reliable results and may support early risk stratification in patients with stroke in emergency department settings.
- 6 March 2025
- Published by Elsevier in American Journal of Infection Control
- Vol. 53 (6) , 732-734
Community and hospital-acquired gram-negative bloodstream infections in non-ICU patients
- 6 March 2025
- Published by Elsevier in American Journal of Infection Control
- Vol. 53 (6) , 732-734
Community and hospital-acquired gram-negative bloodstream infections in non-ICU patients
- 3 November 2024
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 111 (1) , 116592
Evaluation of the filmarray blood culture identification panel on diagnosis of bacteremias in an MDRO-endemic hospital environment
- 3 November 2024
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 111 (1) , 116592
Evaluation of the filmarray blood culture identification panel on diagnosis of bacteremias in an MDRO-endemic hospital environment
- Open Access
- 5 January 2023
- Published by MDPI AG in Antibiotics
- Vol. 12 (1) , 93
In Vitro Synergistic Activity of Antimicrobial Combinations against Carbapenem- and Colistin-Resistant Acinetobacter baumannii and Klebsiella pneumoniae
Polymyxins are commonly used as the last resort for the treatment of MDR Acinetobacter baumannii and Klebsiella pneumoniae nosocomial infections; however, apart from the already known toxicity issues, resistance to these agents is emerging. In the present study, we assessed the in vitro synergistic activity of antimicrobial combinations against carbapenem-resistant and colistin-resistant A. baumannii and K. pneumoniae in an effort to provide more options for their treatment. Two hundred A. baumannii and one hundred and six K. pneumoniae single clinical isolates with resistance to carbapenems and colistin, recovered between 1 January 2021 and 31 July 2022,were included. A. baumannii were tested by the MIC test strip fixed-ratio method for combinations of colistin with either meropenem or rifampicin or daptomycin. K. pneumoniae were tested for the combinations of colistin with meropenem and ceftazidime/avibactam with aztreonam. Synergy was observed at: 98.99% for colistin and meropenem against A. baumannii; 91.52% for colistin and rifampicin; and 100% for colistin and daptomycin. Synergy was also observed at: 73.56% for colistin and meropenem against K. pneumoniae and; and 93% for ceftazidime/avibactam with aztreonam. The tested antimicrobial combinations presented high synergy rates, rendering them valuable options against A. baumannii and K. pneumoniae infections.
- 5 January 2023
- Published by MDPI AG in Antibiotics
- Vol. 12 (1) , 93
Open AccessIn Vitro Synergistic Activity of Antimicrobial Combinations against Carbapenem- and Colistin-Resistant Acinetobacter baumannii and Klebsiella pneumoniae
Polymyxins are commonly used as the last resort for the treatment of MDR Acinetobacter baumannii and Klebsiella pneumoniae nosocomial infections; however, apart from the already known toxicity issues, resistance to these agents is emerging. In the present study, we assessed the in vitro synergistic activity of antimicrobial combinations against carbapenem-resistant and colistin-resistant A. baumannii and K. pneumoniae in an effort to provide more options for their treatment. Two hundred A. baumannii and one hundred and six K. pneumoniae single clinical isolates with resistance to carbapenems and colistin, recovered between 1 January 2021 and 31 July 2022,were included. A. baumannii were tested by the MIC test strip fixed-ratio method for combinations of colistin with either meropenem or rifampicin or daptomycin. K. pneumoniae were tested for the combinations of colistin with meropenem and ceftazidime/avibactam with aztreonam. Synergy was observed at: 98.99% for colistin and meropenem against A. baumannii; 91.52% for colistin and rifampicin; and 100% for colistin and daptomycin. Synergy was also observed at: 73.56% for colistin and meropenem against K. pneumoniae and; and 93% for ceftazidime/avibactam with aztreonam. The tested antimicrobial combinations presented high synergy rates, rendering them valuable options against A. baumannii and K. pneumoniae infections.